HealthDay News– Age is a significant factor in determining aspirin response in patients with stable coronary artery disease (CAD), according to a study published in The American Journal of Cardiology.
Mordehay Vaturi, MD, from Tel-Aviv University in Israel, and colleagues recruited 583 patients with stable CAD who had been treated with aspirin 75 mg/day to 325 mg/day for at least one week.
Patients were divided into two groups based on age; 438 patients made up the group of individuals younger than 75 years, while 145 patients made up the group of patients aged 75 years or older.
The VerifyNow Aspirin Test was used to determine response, and resistance was defined as at least 500 or 550 aspirin reaction units (ARU).
The researchers found that younger and older patients had similar baseline clinical profiles, including relative doses of aspirin therapy. In older of the two groups, the mean VerifyNow Aspirin Test score was significantly higher (450 ± 54 versus 434 ± 53 ARU).
Age remained a significant predictor of the VerifyNow score after adjusting for other variables. When the 500-ARU cut-off was used, aspirin resistance was higher in older patients (19% vs. 11%), but there was no significant difference when the 550-ARU cut-off was used (7% vs. 5%).
“In conclusion, aspirin response differs significantly by age in patients with stable CAD,” the authors wrote.